GlaxoSmithKline will be very picky about new deals

GlaxoSmithKline ($GSK) is taking a back seat at the industry's deal table. CEO Andrew Witty tells Reuters' Ben Hirschler that the company's M&A team has stepped away from doing many new deals right now as the company focuses more on its late-stage pipeline. "Our energy around acquisitions and our machine around acquisition is the lowest it has ever been in the history of the company," says Witty. A few new deals may be executed, he added, to fill a few gaps on technology--like the recent Okairos buyout. For now, though, the pharma giant is more interested in selling noncore assets than adding new ones. Story

 

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.